Michele Anderson Buys 1,111 Shares of Braveheart Bio (NASDAQ:BRVE) Stock

Braveheart Bio, Inc. (NASDAQ:BRVE) insider Michele Anderson purchased 1,111 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was bought at an average cost of $18.00 per share, with a total value of $19,998.00. Following the purchase, the insider owned 332,161 shares of the company’s stock, valued at $5,978,898. This represents a 0.34% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Braveheart Bio Price Performance

Shares of Braveheart Bio stock opened at $30.00 on Friday. Braveheart Bio, Inc. has a 12-month low of $28.47 and a 12-month high of $32.00.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.